Crystal structure of the DNA cytosine deaminase APOBEC3F: The catalytically active and HIV-1 Vif-binding domain

Structure

Volumn 21, Issue 6, 2013, Pages 1042-1050

  Bohn, Markus Frederik ^a   Shandilya, Shivender M D ^a   Albin, John S ^b   Kouno, Takahide ^b   Anderson, Brett D ^b   McDougle, Rebecca M ^b   Carpenter, Michael A ^b   Rathore, Anurag ^b   Evans, Leah ^b   Davis, Ahkillah N ^b   Zhang, Jingying ^b   Lu, Yongjian ^b   Somasundaran, Mohan ^a   Matsuo, Hiroshi ^b   Harris, Reuben S ^b   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; CYTOSINE DEAMINASE; VIF PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; GENETIC CONSERVATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION;

CATALYSIS; CRYSTALLOGRAPHY, X-RAY; CYTOSINE DEAMINASE; HIV-1; MODELS, MOLECULAR; PROTEIN CONFORMATION; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878866554     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2013.04.010     Document Type: Article

References (64)

1. J.S. Albin, and R.S. Harris Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics Expert Rev. Mol. Med. 12 2010 e4
2. J.S. Albin, G. Haché, J.F. Hultquist, W.L. Brown, and R.S. Harris Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function J. Virol. 84 2010 10209 10219
3. J.S. Albin, R.S. LaRue, J.A. Weaver, W.L. Brown, K. Shindo, E. Harjes, H. Matsuo, and R.S. Harris A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif J. Biol. Chem. 285 2010 40785 40792
4. S.F. Altschul, T.L. Madden, A.A. Schäffer, J. Zhang, Z. Zhang, W. Miller, and D.J. Lipman Gapped BLAST and PSI-BLAST: a new generation of protein database search programs Nucleic Acids Res. 25 1997 3389 3402
5. J.R. Auclair, K.M. Green, S. Shandilya, J.E. Evans, M. Somasundaran, and C.A. Schiffer Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity Proteins 69 2007 270 284
6. M. Biasin, M. Clerici, and L. Piacentini Innate immunity in resistance to HIV infection J. Infect. Dis. 202 Suppl 3 2010 S361 S365
7. K.N. Bishop, R.K. Holmes, A.M. Sheehy, N.O. Davidson, S.J. Cho, and M.H. Malim Cytidine deamination of retroviral DNA by diverse APOBEC proteins Curr. Biol. 14 2004 1392 1396
8. E.P. Browne, C. Allers, and N.R. Landau Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent Virology 387 2009 313 321
9. M.B. Burns, L. Lackey, M.A. Carpenter, A. Rathore, A.M. Land, B. Leonard, E.W. Refsland, D. Kotandeniya, N. Tretyakova, and J.B. Nikas APOBEC3B is an enzymatic source of mutation in breast cancer Nature 494 2013 366 370
10. M.A. Carpenter, E. Rajagurubandara, P. Wijesinghe, and A.S. Bhagwat Determinants of sequence-specificity within human AID and APOBEC3G DNA Repair (Amst.) 9 2010 579 587
11. K.-M.M. Chen, E. Harjes, P.J. Gross, A. Fahmy, Y. Lu, K. Shindo, R.S. Harris, and H. Matsuo Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G Nature 452 2008 116 119
12. Y.L. Chiu, and W.C. Greene The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements Annu. Rev. Immunol. 26 2008 317 353
13. S.G. Conticello The AID/APOBEC family of nucleic acid mutators Genome Biol. 9 2008 229
14. S.G. Conticello Creative deaminases, self-inflicted damage, and genome evolution Ann. NY Acad. Sci. 1267 2012 79 85
15. A. Furukawa, T. Nagata, A. Matsugami, Y. Habu, R. Sugiyama, F. Hayashi, N. Kobayashi, S. Yokoyama, H. Takaku, and M. Katahira Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G EMBO J. 28 2009 440 451
16. B.D. Gooch, and B.R. Cullen Functional domain organization of human APOBEC3G Virology 379 2008 118 124
17. J.U. Guo, Y. Su, C. Zhong, G.-L. Ming, and H. Song Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain Cell 145 2011 423 434
18. C.E. Hamilton, F.N. Papavasiliou, and B.R. Rosenberg Diverse functions for DNA and RNA editing in the immune system RNA Biol. 7 2010 220 228
19. Y. Han, X. Wang, Y. Dang, and Y.H. Zheng APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication PLoS Pathog. 4 2008 e1000095
20. E. Harjes, P.J. Gross, K.-M.M. Chen, Y. Lu, K. Shindo, R. Nowarski, J.D. Gross, M. Kotler, R.S. Harris, and H. Matsuo An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model J. Mol. Biol. 389 2009 819 832
21. R.S. Harris, S.K. Petersen-Mahrt, and M.S. Neuberger RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators Mol. Cell 10 2002 1247 1253
22. R.S. Harris, K.N. Bishop, A.M. Sheehy, H.M. Craig, S.K. Petersen-Mahrt, I.N. Watt, M.S. Neuberger, and M.H. Malim DNA deamination mediates innate immunity to retroviral infection Cell 113 2003 803 809
23. R.S. Harris, J.F. Hultquist, and D.T. Evans The restriction factors of human immunodeficiency virus J. Biol. Chem. 287 2012 40875 40883
24. L.G. Holden, C. Prochnow, Y.P. Chang, R. Bransteitter, L. Chelico, U. Sen, R.C. Stevens, M.F. Goodman, and X.S. Chen Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications Nature 456 2008 121 124
25. R.K. Holmes, M.H. Malim, and K.N. Bishop APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32 2007 118 128
26. R.K. Holmes, F.A. Koning, K.N. Bishop, and M.H. Malim APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G J. Biol. Chem. 282 2007 2587 2595
27. H. Huthoff, and M.H. Malim Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation J. Virol. 81 2007 3807 3815
28. S. Jäger, D.Y. Kim, J.F. Hultquist, K. Shindo, R.S. LaRue, E. Kwon, M. Li, B.D. Anderson, L. Yen, and D. Stanley Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection Nature 481 2011 371 375
29. S. Kao, M.A. Khan, E. Miyagi, R. Plishka, A. Buckler-White, and K. Strebel The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity J. Virol. 77 2003 11398 11407
30. S. Kitamura, H. Ode, M. Nakashima, M. Imahashi, Y. Naganawa, T. Kurosawa, Y. Yokomaku, T. Yamane, N. Watanabe, and A. Suzuki The APOBEC3C crystal structure and the interface for HIV-1 Vif binding Nat. Struct. Mol. Biol. 19 2012 1005 1010
31. R.M. Kohli, S.R. Abrams, K.S. Gajula, R.W. Maul, P.J. Gearhart, and J.T. Stivers A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase J. Biol. Chem. 284 2009 22898 22904
32. J.F. Kreisberg, W. Yonemoto, and W.C. Greene Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation J. Exp. Med. 203 2006 865 870
33. E. Krissinel, and K. Henrick Inference of macromolecular assemblies from crystalline state J. Mol. Biol. 372 2007 774 797
34. R.S. LaRue, S.R. Jónsson, K.A. Silverstein, M. Lajoie, D. Bertrand, N. El-Mabrouk, I. Hötzel, V. Andrésdóttir, T.P. Smith, and R.S. Harris The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals BMC Mol. Biol. 9 2008 104
35. R.S. LaRue, V. Andrésdóttir, Y. Blanchard, S.G. Conticello, D. Derse, M. Emerman, W.C. Greene, S.R. Jónsson, N.R. Landau, and M. Löchelt Guidelines for naming nonprimate APOBEC3 genes and proteins J. Virol. 83 2009 494 497
36. R.S. LaRue, J. Lengyel, S.R. Jónsson, V. Andrésdó ttir, and R.S. Harris Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity J. Virol. 84 2010 8193 8201
37. D. Lecossier, F. Bouchonnet, F. Clavel, and A.J. Hance Hypermutation of HIV-1 DNA in the absence of the Vif protein Science 300 2003 1112
38. M. Li, S.M. Shandilya, M.A. Carpenter, A. Rathore, W.L. Brown, A.L. Perkins, D.A. Harki, J. Solberg, D.J. Hook, and K.K. Pandey First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G ACS Chem. Biol. 7 2012 506 517
39. M.T. Liddament, W.L. Brown, A.J. Schumacher, and R.S. Harris APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo Curr. Biol. 14 2004 1385 1391
40. B. Mangeat, P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts Nature 424 2003 99 103
41. E. Miyagi, S. Opi, H. Takeuchi, M. Khan, R. Goila-Gaur, S. Kao, and K. Strebel Enzymatically active APOBEC3G is required for efficient inhibition of HIV-1 J. Virol. 81 2007 13346 13353
42. E.N. Newman, R.K. Holmes, H.M. Craig, K.C. Klein, J.R. Lingappa, M.H. Malim, and A.M. Sheehy Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity Curr. Biol. 15 2005 166 170
43. S. Nik-Zainal, L.B. Alexandrov, D.C. Wedge, P. Van Loo, C.D. Greenman, K. Raine, D. Jones, J. Hinton, J. Marshall, L.A. Stebbings Breast Cancer Working Group of the International Cancer Genome Consortium Mutational processes molding the genomes of 21 breast cancers Cell 149 2012 979 993
44. C. Prochnow, R. Bransteitter, M.G. Klein, M.F. Goodman, and X.S. Chen The APOBEC-2 crystal structure and functional implications for the deaminase AID Nature 445 2007 447 451
45. T.H. Reingewertz, H. Benyamini, M. Lebendiker, D.E. Shalev, and A. Friedler The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state Protein Eng. Des. Sel. 22 2009 281 287
46. T.H. Reingewertz, D.E. Shalev, and A. Friedler Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure Protein Pept. Lett. 17 2010 988 998
47. S.A. Roberts, J. Sterling, C. Thompson, S. Harris, D. Mav, R. Shah, L.J. Klimczak, G.V. Kryukov, E. Malc, and P.A. Mieczkowski Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions Mol. Cell 46 2012 424 435
48. A.J. Schumacher, G. Haché, D.A. Macduff, W.L. Brown, and R.S. Harris The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction J. Virol. 82 2008 2652 2660
49. S.M.D. Shandilya, M.N.L. Nalam, E.A. Nalivaika, P.J. Gross, J.C. Valesano, K. Shindo, M. Li, M. Munson, W.E. Royer, and E. Harjes Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces Structure 18 2010 28 38
50. A.M. Sheehy, N.C. Gaddis, J.D. Choi, and M.H. Malim Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein Nature 418 2002 646 650
51. J.H.M. Simon, A.M. Sheehy, E.A. Carpenter, R.A.M. Fouchier, and M.H. Malim Mutational analysis of the human immunodeficiency virus type 1 Vif protein J. Virol. 73 1999 2675 2681
52. J.L. Smith, and V.K. Pathak Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif J. Virol. 84 2010 12599 12608
53. C. Song, L. Sutton, M.E. Johnson, R.T. D'Aquila, and J.P. Donahue Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction J. Biol. Chem. 287 2012 16965 16974
54. M.D. Stenglein, M.B. Burns, M. Li, J. Lengyel, and R.S. Harris APOBEC3 proteins mediate the clearance of foreign DNA from human cells Nat. Struct. Mol. Biol. 17 2010 222 229
55. K. Strebel APOBEC3G & HTLV-1: inhibition without deamination Retrovirology 2 2005 37
56. X. Wang, P.T. Dolan, Y. Dang, and Y.H. Zheng Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle J. Biol. Chem. 282 2007 1585 1594
57. M. Wang, C. Rada, and M.S. Neuberger Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID J. Exp. Med. 207 2010 141 153
58. H.L. Wiegand, B.P. Doehle, H.P. Bogerd, and B.R. Cullen A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins EMBO J. 23 2004 2451 2458
59. B. Yang, L. Gao, L. Li, Z. Lu, X. Fan, C.A. Patel, R.J. Pomerantz, G.C. DuBois, and H. Zhang Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins J. Biol. Chem. 278 2003 6596 6602
60. X. Yu, Y. Yu, B. Liu, K. Luo, W. Kong, P. Mao, and X.F. Yu Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex Science 302 2003 1056 1060
61. V. Zennou, and P.D. Bieniasz Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates Virology 349 2006 31 40
62. H. Zhang, B. Yang, R.J. Pomerantz, C. Zhang, S.C. Arunachalam, and L. Gao The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA Nature 424 2003 94 98
63. W. Zhang, J. Du, S.L. Evans, Y. Yu, and X.-F. Yu T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction Nature 481 2012 376 379
64. Y.-H. Zheng, D. Irwin, T. Kurosu, K. Tokunaga, T. Sata, and B.M. Peterlin Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication J. Virol. 78 2004 6073 6076